1. PI3K/Akt/mTOR
    Stem Cell/Wnt
    Cell Cycle/DNA Damage
    Autophagy
  2. PI3K
    Casein Kinase
    Autophagy

LY294002 (Synonyms: NSC 697286; SF 1101)

Cat. No.: HY-10108 Purity: 99.97%
Data Sheet SDS Handling Instructions

LY294002 is a broad-spectrum inhibitor of PI3K, with IC50 of 0.5/0.57/0.97 μM for PI3Kα/δ/β, respectively, also potently inhibits CK2 with IC50 of 98 nM.

For research use only. We do not sell to patients.
LY294002 Chemical Structure

LY294002 Chemical Structure

CAS No. : 154447-36-6

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
10 mg $50 In-stock
50 mg $70 In-stock
100 mg $90 In-stock
200 mg $130 In-stock
500 mg $285 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Customer Review

    LY294002 purchased from MCE. Usage Cited in: J Cancer. 2016 Jun 5;7(9):1114-24.

    Effects of PI3K inhibition. (A) Protein levels of p-AKT S473 . (B) Inhibition of PI3K dose-dependently decreased the levels of p-EphA2S897 in vitro.

    LY294002 purchased from MCE. Usage Cited in: Cell Physiol Biochem. 2016;40:579-588.

    LY294002, a highly selective AKT inhibitor, completely blocks GSK3β phosphorylation induced by SDT. Effect of SDT on the expression of p-SMAD3, p-AKT and p-GSK3β. Images of p-GSK3β, GSK3β and GAPDH protein and mean values of protein level (relative to GAPDH) in cells.

    LY294002 purchased from MCE. Usage Cited in: Biomedical Research 2017; 28 (8): 3383-3386

    Effects of various protease inhibitors on HO-1 and P-gp protein expressions.

    LY294002 purchased from MCE. Usage Cited in: Environ Pollut. 2017 Oct;229:964-975.

    NF-κB-dependent immune responses in testicular cells. Sertoli cells (SC), Leydig cells (LC), and germ cells (GC) are pretreated with BAY11-7082 (BAY) at 2 μM for 1 h, followed by the addition of MC-LR into the culture medium to a final concentration of 1 μM and incubation for 6 h. Expression of phosphorylated NF-κB p65 (p-p65) and total p65 is measured by western blotting. The ratio of p-65/p65 is determined by densitometry and is expressed as means±SEM (n=5).

    LY294002 purchased from MCE. Usage Cited in: Environ Pollut. 2017 Oct;229:964-975.

    Inhibition of PI3K/AKT blocks MC-LR-induced NF-κB activation. SC, LC, and GC are pretreated with the PI3K/AKT inhibitor LY294002 (LY) at 20 μM for 1 h followed by a 6-h treatment with MC-LR. Expression of phosphorylated NF-κB p65 (p-p65) and total p65 are detected by western blotting.

    LY294002 purchased from MCE. Usage Cited in: Cell Mol Life Sci. 2017 Oct 25.

    Sertoli cells (SC) are pretreated with BAY11-7082 at 2 μM for 1 h, followed by the addition of MC-LR into the culture medium. Expression of p-p65 and MMP-8 is measured by western blotting.

    LY294002 purchased from MCE. Usage Cited in: Cell Mol Life Sci. 2017 Oct 25.

    Sertoli cells (SC) are pretreated with LY294002 at 20 μM for 1 h followed by a 24-h treatment with MC-LR. Expression levels of p-p65 and MMP-8 are detected by western blotting.

    LY294002 purchased from MCE. Usage Cited in: Cell Mol Life Sci. 2017 Oct 25.

    Sertoli cells (SC) are pretreated with the PD98059 for 1 h followed by a 24-h treatment with MC-LR. Expression levels of MMP-8, c-Jun, c-Fos, p-ERK, ERK, p-JNK, and JNK are determined by western blotting.

    LY294002 purchased from MCE. Usage Cited in: Cell Mol Life Sci. 2017 Oct 25.

    Sertoli cells (SC) are pretreated with the SP600125 for 1 h followed by a 24-h treatment with MC-LR. Expression levels of MMP-8, c-Jun, c-Fos, p-ERK, ERK, p-JNK, and JNK are determined by western blotting.

    LY294002 purchased from MCE. Usage Cited in: Exp Gerontol. 2017 Oct 25;100:77-86.

    Cells are treated with LY294002 5 μM for 2 h followed by treated with MANF 200 ng/mL for another 12 h, and then cell lysates are immunoblotted to assess the phosphorylation of Akt, GSK3β, and Nrf2.

    LY294002 purchased from MCE. Usage Cited in: Exp Gerontol. 2017 Oct 25;100:77-86.

    Cells are treated with ML385 at the concentration of 5 μM for 12 h. The expression of Nrf2 and its translocation into nucleus are determined using western blot analysis.

    LY294002 purchased from MCE. Usage Cited in: J Mol Med (Berl). 2017 Nov 3.

    The regulation of PHP14 on Akt phosphorylation is possibly via PI3Kγ in LX-2 cells. Cells are serum starvation 24 h, then treated TGF-β1 (10 ng/mL) 2 h, then added LY294002 (5 μM) or AS252424 (10 μM) as indicated; after another 2 h incubation, Western blot is performed to assess the protein expression of p-Akt.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    LY294002 is a broad-spectrum inhibitor of PI3K, with IC50 of 0.5/0.57/0.97 μM for PI3Kα/δ/β, respectively, also potently inhibits CK2 with IC50 of 98 nM.

    IC50 & Target

    IC50: 0.5/0.57/0.97 μM (PI3Kα/δ/β)[1]
    IC50: 98 nM (CK2)[2]

    In Vitro

    LY294002 (5 μM) completely inhibits the phosphorylation of PKB In HepG2 cells. LY294002 (5 μM) is also shown to block insulin-induced phosphorylation of PKB Ser473 in CHO-IR cells[1]. LY294002 is also a potent inhibitor of CK2 (casein kinase 2) with IC50 of 98 nM. LY294002 is also able to reduce the kinase activity of both isoforms of the serine/threonine kinases GSK3α and β[2]. When the CNE-2Z cell line is cultured in medium containing LY294002(0 μM, 10 μM, 25 μM, 50 μM, and 75 μM) for 24 h and 48 h, cell proliferation is remarkably decreased in a dose-dependent fashion[3].

    In Vivo

    Treatment with LY294002 (i.p.,50 mg/kg, 75 mg/kg) significantly reduces mean NPC tumor burden as compared with the control group. Treatment with 10 mg/kg or 25 mg/kg LY294002 is less effective in decreasing tumor burden. Mean NPC tumor burden treated with LY294002 is remarkably decreased in a dose-dependent manner, whereas mean body weight is no obvious difference between control and treated groups (LY294002, 10 mg/kg, 25 mg/kg, 50 mg/kg, and 75 mg/kg)[3].

    References
    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 3.2537 mL 16.2686 mL 32.5373 mL
    5 mM 0.6507 mL 3.2537 mL 6.5075 mL
    10 mM 0.3254 mL 1.6269 mL 3.2537 mL
    Please refer to the solubility information to select the appropriate solvent.
    Kinase Assay
    [2]

    PI3K inhibition by PI828 and LY294002 is determined in a radiometric assay using purified, recombinant enzymes (class IA and class IB) with 1 μM ATP. The kinase reaction is carried out for 1 h at room temperature (24°C) and is terminated by addition of PBS. IC50 values are subsequently determined using a sigmoidal dose-response curve fit (variable slope). CK2 and GSK3β (glycogen synthase kinase 3β) inhibition is established by kinase selectivity screening. Inhibitor (10 μM; PI828 and LY294002) is tested against the Upstate panel of kinases in 10 μM ATP[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay
    [3]

    LY294002 is dissolved in DMSO and stored, and then diluted with appropriate media (DMSO 0.5%) before use[3].

    Human nasopharyngeal carcinoma cell line CNE-2Z is seeded into 96-well plates at 5000 cells/well. Twenty-four hours after cells are seeded, the medium is removed and replaced in the presence of LY294002 (0 μM, 10 μM, 25 μM, 50 μM, and 75 μM) dissolved in DMSO or DMSO only for an additional 24 h and 48 h. To avoid any nonspecific toxic effects of DMSO on cell growth, DMSO concentrations are maintained at 0.5% in all experiments. MTT dye (5 mg/mL) is added to each well. The reaction is stopped by the addition of DMSO, and optical density is measured at 490 nm on a multiwell plate reader. Background absorbance of the medium in the absence of cells is subtracted. All samples are assayed in triplicate, and the mean for each experiment is calculated. Results are expressed as a percentage of control, which is considered to be 100%[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [3][4]

    LY294002 is dissolved in vehicle (DMSO).

    Mice[3]
    Athymic nude mice are used when they are 6-8 weeks. Mice are randomly divided into free separated into five groups (n=4 mice). Mice are housed in the same environment with controlled temperature, humidity, and a 12 h light/dark cycle. Mice are inoculated subcutaneously with CNE-2Z cells (1×106 cells/mouse in 200 μL of RPMI-1640) into the flank. The tumor take rate is 100%. After 1 week, an intraperitoneal injection is performed to the xenograft mice with different dosage of LY294002 (10 mg/kg, 25 mg/kg, 50 mg/kg, and 75 mg/kg twice weekly (n=4 mice), each group for 4 weeks. Treated mice are monitored any signs. Body weight and tumors size are measured twice a week. Tumor size is measured using calipers and tumor volume is calculated (volume=long axis×short axis2). At the end of the treatment, all mice are euthanized. One part of tumor tissue is fixed in formalin and embedded in paraffin, and another part is stored at -70°C.
    Rat[4]
    Male Sprague-Dawley rats weighing 220-240 g are anesthetized by intraperitoneally injecting pentobarbital sodium (50 mg/kg). The animals are divided into 3 groups: NMDA+vehicle (DMSO) (n=46), NMDA+LY294002 (50 nmol) (n=25), and NMDA+Wortmannin (50 nmol) (n=23). Either LY294002 or wortmannin mixed with 200 nmol of NMDA in a total volume of 5 μL is injected into the vitreous cavity of one eye. The same volume of DMSO is injected into the vitreous cavity of the contralateral eye, which is used as a control. The injections are performed under a microscope using a 32-gauge needle, which is connected to a microsyringe. The needle is inserted approximately 1 mm behind the corneal limbus. Damage to neurons and blood vessels in the retina is assessed at 2 and 7 days after the injection. The effects of the intravitreal treatment with either LY294002 or Wortmannin alone on retinal neurons and blood vessels are also examined. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    307.34

    Formula

    C₁₉H₁₇NO₃

    CAS No.

    154447-36-6

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: 14.9 mg/mL

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Purity: 99.97%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    LY294002
    Cat. No.:
    HY-10108
    Quantity: